Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) EBT (2021 - 2025)

Historic EBT for Verrica Pharmaceuticals (VRCA) over the last 5 years, with Q3 2025 value amounting to -$308000.0.

  • Verrica Pharmaceuticals' EBT rose 9865.26% to -$308000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$24.3 million, marking a year-over-year increase of 7147.24%. This contributed to the annual value of -$73.9 million for FY2024, which is 1035.07% down from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' EBT stood at -$308000.0, which was up 9865.26% from -$393000.0 recorded in Q2 2025.
  • Over the past 5 years, Verrica Pharmaceuticals' EBT peaked at $1.5 million during Q3 2022, and registered a low of -$24.8 million during Q3 2023.
  • In the last 5 years, Verrica Pharmaceuticals' EBT had a median value of -$10.2 million in 2022 and averaged -$11.0 million.
  • Its EBT has fluctuated over the past 5 years, first soared by 11180.92% in 2022, then crashed by 173379.54% in 2023.
  • Over the past 5 years, Verrica Pharmaceuticals' EBT (Quarter) stood at -$9.5 million in 2021, then skyrocketed by 37.89% to -$5.9 million in 2022, then crashed by 316.02% to -$24.6 million in 2023, then soared by 45.01% to -$13.6 million in 2024, then surged by 97.73% to -$308000.0 in 2025.
  • Its EBT was -$308000.0 in Q3 2025, compared to -$393000.0 in Q2 2025 and -$10.0 million in Q1 2025.